LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Начало・Списък с акции・Merck & Co Inc.

Merck & Co Inc.

Затворен

СекторЗдравеопазване

112.58 1.16

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

110.97

Максимум

112.86

Ключови измерители
By Trading Economics
Приходи	-7.2B -4.2B
Продажби	-114M 16B
P/E Средно за сектора	31.347 51.415
EPS	-1.28
Дивидентна доходност	2.94
Марж на печалбата	-26.053
Служители	73,000
EBITDA	-6.2B -1.9B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+21.75% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	2.94% 2.34%
Следващи печалби	4.08.2026 г.
Следваща дата на дивидент	7.07.2026 г.
Следваща дата на екс-дивидент	15.06.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.6B 275B
Предишно отваряне	111.42
Предишно затваряне	112.58

Настроения в новините

By Acuity

54%

46%

249 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

76.03 / 83.28 Подкрепа & съпротива

Merck & Co Inc. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.04.2026 г., 14:20 ч. UTC

Печалби

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30.04.2026 г., 10:45 ч. UTC

Печалби

Merck 1Q Sales Rise on Continued Keytruda Growth

5.05.2026 г., 18:12 ч. UTC

Печалби

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5.05.2026 г., 13:54 ч. UTC

Печалби

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5.05.2026 г., 12:48 ч. UTC

Придобивния, сливания и поглъщания

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5.05.2026 г., 12:48 ч. UTC

Придобивния, сливания и поглъщания

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5.05.2026 г., 12:47 ч. UTC

Придобивния, сливания и поглъщания

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5.05.2026 г., 12:45 ч. UTC

Придобивния, сливания и поглъщания

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1.05.2026 г., 18:35 ч. UTC

Печалби

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1.05.2026 г., 14:53 ч. UTC

Печалби

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30.04.2026 г., 13:27 ч. UTC

Печалби

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30.04.2026 г., 10:47 ч. UTC

Печалби

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck 1Q Animal Health Sales Up 13% >MRK

30.04.2026 г., 10:30 ч. UTC

Печалби

Merck 1Q Sales $16.29B >MRK

Сравнение с други в отрасъла

Ценова промяна

Merck & Co Inc. Прогноза

Ценова цел

By TipRanks

21.75% нагоре

12-месечна прогноза

Среден 135.61 USD 21.75%

Висок 179 USD

Нисък 112 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Merck & Co Inc. през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Merck & Co Inc. през последните 3 месеца.

Техническа оценка

By Trading Central

76.03 / 83.28Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

249 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.